Yes. Thanks, Vincent. Well, first of all, historically, I don't want to brag, but historically, we've actually nailed it pretty well compared to some of the external consultants on the builds because we got so many people in the plants every day. We have visibility to operating schedules, and we talk to those folks. So, the difference for us in Q1 specifically is China. Because our base case is that there will be, to some degree, a second wave after Chinese New Year of infections, and we saw what that did on the first wave to assembly plants and other suppliers. So that's our base case, and that may explain the difference between us and some of the consulting houses out there. But beyond that, we're expecting modest growth for the year, low single digits. And that's an area where there potentially could be upside, but our base case is low single digits. Yes, just to give you some examples specifically of what happened on the ground in China, and why we are a bit cautious on the post-Chinese New Year. When things opened up in mid China -- I'm sorry, mid-December in China, we've got 19 PPG manufacturing sites across the country. And we went from near zero absenteeism very quickly to above 50% absenteeism across that whole network. And that has returned very rapidly to near zero in a period of about 2.5 to 3 weeks. And we saw that same in some of our other suppliers, assembly plants, you name it. So we've lived it, we've seen the data, and we believe that as people travel to the families that more travel than the last three years across China for Chinese New Year, as they travel to some of the more remote villages to visit their families in return, we do believe there will be a short, but acute second wave. And so that's why we're a bit more cautious. And as Vince mentioned, March is a huge month normally for our China business.